ID   RINI_PANTR              Reviewed;         461 AA.
AC   Q8HZP9;
DT   21-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   03-AUG-2022, entry version 102.
DE   RecName: Full=Ribonuclease inhibitor;
DE   AltName: Full=Ribonuclease/angiogenin inhibitor 1;
GN   Name=RNH1; Synonyms=RNH;
OS   Pan troglodytes (Chimpanzee).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Pan.
OX   NCBI_TaxID=9598;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=12524352; DOI=10.1093/genetics/162.4.1825;
RA   Zhang J., Webb D.M., Podlaha O.;
RT   "Accelerated protein evolution and origins of human-specific features:
RT   Foxp2 as an example.";
RL   Genetics 162:1825-1835(2002).
CC   -!- FUNCTION: Ribonuclease inhibitor which inhibits RNASE1, RNASE2 and ANG.
CC       May play a role in redox homeostasis (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Forms high-affinity heterodimers with RNASE1, ANG and RNASE2.
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- DOMAIN: The LRR domain forms a horseshoe-shaped structure that
CC       interacts tightly with target RNases via a large protein interaction
CC       surface on its interior side. {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF539549; AAN10133.1; -; mRNA.
DR   RefSeq; NP_001009060.1; NM_001009060.1.
DR   RefSeq; XP_016775242.1; XM_016919753.1.
DR   RefSeq; XP_016775243.1; XM_016919754.1.
DR   RefSeq; XP_016775244.1; XM_016919755.1.
DR   RefSeq; XP_016775245.1; XM_016919756.1.
DR   RefSeq; XP_016775246.1; XM_016919757.1.
DR   RefSeq; XP_016775247.1; XM_016919758.1.
DR   RefSeq; XP_016775248.1; XM_016919759.1.
DR   RefSeq; XP_016775249.1; XM_016919760.1.
DR   RefSeq; XP_016775250.1; XM_016919761.1.
DR   AlphaFoldDB; Q8HZP9; -.
DR   SMR; Q8HZP9; -.
DR   STRING; 9598.ENSPTRP00000054947; -.
DR   PaxDb; Q8HZP9; -.
DR   Ensembl; ENSPTRT00000062390; ENSPTRP00000054947; ENSPTRG00000003118.
DR   Ensembl; ENSPTRT00000097661; ENSPTRP00000069850; ENSPTRG00000003118.
DR   GeneID; 450154; -.
DR   KEGG; ptr:450154; -.
DR   CTD; 6050; -.
DR   eggNOG; KOG4308; Eukaryota.
DR   GeneTree; ENSGT00940000161492; -.
DR   InParanoid; Q8HZP9; -.
DR   OMA; GGNDIHA; -.
DR   OrthoDB; 710473at2759; -.
DR   Proteomes; UP000002277; Chromosome 11.
DR   Bgee; ENSPTRG00000003118; Expressed in dorsolateral prefrontal cortex and 22 other tissues.
DR   GO; GO:0032311; C:angiogenin-PRI complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR   GO; GO:0008428; F:ribonuclease inhibitor activity; IBA:GO_Central.
DR   GO; GO:0045765; P:regulation of angiogenesis; IBA:GO_Central.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR006553; Leu-rich_rpt_Cys-con_subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR041302; LRR_RI_cap.
DR   Pfam; PF13516; LRR_6; 6.
DR   Pfam; PF18779; LRR_RI_capping; 1.
DR   SMART; SM00367; LRR_CC; 5.
PE   2: Evidence at transcript level;
KW   Acetylation; Cytoplasm; Leucine-rich repeat; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P13489"
FT   CHAIN           2..461
FT                   /note="Ribonuclease inhibitor"
FT                   /id="PRO_0000097345"
FT   REPEAT          20..48
FT                   /note="LRR 1"
FT   REPEAT          49..76
FT                   /note="LRR 2"
FT   REPEAT          77..105
FT                   /note="LRR 3"
FT   REPEAT          106..133
FT                   /note="LRR 4"
FT   REPEAT          134..162
FT                   /note="LRR 5"
FT   REPEAT          163..190
FT                   /note="LRR 6"
FT   REPEAT          191..219
FT                   /note="LRR 7"
FT   REPEAT          220..247
FT                   /note="LRR 8"
FT   REPEAT          248..276
FT                   /note="LRR 9"
FT   REPEAT          277..304
FT                   /note="LRR 10"
FT   REPEAT          305..333
FT                   /note="LRR 11"
FT   REPEAT          334..361
FT                   /note="LRR 12"
FT   REPEAT          362..390
FT                   /note="LRR 13"
FT   REPEAT          391..418
FT                   /note="LRR 14"
FT   REPEAT          419..447
FT                   /note="LRR 15"
FT   REGION          2..11
FT                   /note="2 X 5 AA tandem repeats of S-L-D-I-Q"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P13489"
FT   MOD_RES         91
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P13489"
SQ   SEQUENCE   461 AA;  49929 MW;  5C41BECC53ECA693 CRC64;
     MSLDIQSLDI QCEELSDARW AELLPLLQQC QVVRLDDCGL TEARCKDISS ALRVNPALAE
     LNLRSNELGD VGVHCVLQGL QSPSCKIQKL SLQNCCLTGA GCGVLSSTLR TLPTLQELHL
     SDNLLGDAGL QLLCEGLLDP QCRLEKLQLE YCNLSAASCK PLASVLRAKP DFKELTVSNN
     DINEAGVRVL CQGLKDSPCQ LEALKLESCG VTSDNCRDLC GIVASKASLR ELALGSNKLG
     DVGMAELCPG LLHPSSRLRT LWIWECGITA KGCGDLCRVL RAKESLKELS LAGNELGDEG
     ARLLCETLLE PGCQLESLWV KSCSFTAACC SHFSSVLAQN KFLLELQISN NRLEDAGVQE
     LCQGLGQPGS VLRVLWLADC DVSDSSCSSL AATLLANHSL RELDLSNNCL GDAGILQLVE
     SVRQPGCLLE QLVLYDIYWS EEMEDRLQAL EKDKPSLRVI S